Page 6 - Novo Nordisk Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Broad Institute of MIT and Harvard today announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases. The collaboration will focus on advancing three programs over the next three years. Two programs aim to identify drug targets for clinically important subtypes of type 2 diabetes, which affects more than 37 million people in the United States alone, and one program aims to unravel the genetic roots of cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.

United statesUnited kingdomUli stilzJose florezNovo nordisk bioPatrick ellinorTodd golubDiabetes research groupBroad instituteNovo nordiskDepartment of medicineCardiovascular disease initiativeDevelopment of therapeuticsCorrigan minehan heart centerBio innovation hubDiabetes research